These findings are in accordance with our preliminary work [29] but in contradiction with the results obtained by Matveyenko et al. [37] using a DPP IV inhibitor in human IAPP transgenic (HIP) rats and by Nachnani et al. [41] using an injection of GLP-1 agonist, who suggest that the enhancement of endogenous GLP-1 levels could induce undetected low grade asymptomatic chronic pancreatitis. The gene discussed is DPP4; the disease is chronic pancreatitis.